Sign in
Author
|
Conference
|
Journal
|
Organization
|
Year
|
DOI
Look for results that meet for the following criteria:
since
equal to
before
between
and
Search in all fields of study
Limit my searches in the following fields of study
Agriculture Science
Arts & Humanities
Biology
Chemistry
Computer Science
Economics & Business
Engineering
Environmental Sciences
Geosciences
Material Science
Mathematics
Medicine
Physics
Social Science
Multidisciplinary
Keywords
(10)
Chronic Hepatitis B
Hepatitis B Virus
Liver Fibrosis
Side Effect
Hepatocellular Carcinoma
High Sensitivity
Nucleotides
Post Treatment
sustained virologic response
Widely Linear
Subscribe
Academic
Publications
Treatment of chronic hepatitis B: Update of the recommendations from the 2007 Italian Workshop
Treatment of chronic hepatitis B: Update of the recommendations from the 2007 Italian Workshop,10.1016/j.dld.2010.10.014,Digestive and Liver Disease,G
Edit
Treatment of chronic hepatitis B: Update of the recommendations from the 2007 Italian Workshop
BibTex
|
RIS
|
RefWorks
Download
Giampiero Carosi
,
Mario Rizzetto
,
Alfredo Alberti
,
Giuseppe Cariti
,
Massimo Colombo
,
Antonio Craxì
,
Gaetano Filice
,
Massimo Levrero
,
Francesco Mazzotta
,
Giuseppe Pastore
,
Felice Piccinino
,
Daniele Prati
http://academic.research.microsoft.com/io.ashx?type=5&id=49645879&selfId1=0&selfId2=0&maxNumber=12&query=
The Italian recommendations for the therapy of
hepatitis B virus
(HBV)-related disease were issued in 2008. Subsequently in 2008 the nucleotide analogue (NA) Tenofovir was approved for antiviral treatment. The introduction of this important new drug has called for the current guidelines update, which includes some additional revisions: (a) the indication for therapy is extended to mild
liver fibrosis
and the indication for treatment is graded as “possible”, “optional” or “mandatory” according to the fibrosis stage; (b) two different treatment strategies are described: first line definite duration treatment with interferon, long-term treatment of indefinite duration with NA; (c) the indication to follow either strategy is also based on the stage of liver fibrosis; (d) virological monitoring is modified to include the definitions of failure and of sustained
virological response
to interferon therapy; (e) the recommendation to use HBV DNA assays with
high sensitivity
and wide linear ranges is underlined (f) guidelines on post-treatment follow-up after finite treatment with NA, potential side effects of therapy and non-virological monitoring are defined; (g) definitions and treatment of patients without optimal response to NA are reported; (f) treatment and monitoring of compensated or decompensated cirrhosis and
hepatocellular carcinoma
are updated.
Journal:
Digestive and Liver Disease - DIG LIVER DIS
, vol. 43, no. 4, pp. 259-265, 2011
DOI:
10.1016/j.dld.2010.10.014
Cumulative
Annual
View Publication
The following links allow you to view full publications. These links are maintained by other sources not affiliated with Microsoft Academic Search.
(
www.sciencedirect.com
)